Advances in Glioblastoma: Bridging Genetics, Epigenetics, Immunology and Pathophysiology to Advanced Therapies

Dear Colleagues,

Glioblastoma (GBM) stands as one of the most challenging brain tumors, representing a paradigm of complexity both in its nature and therapeutic resistance. Integral to this complexity is the nuanced interplay of immunological responses and a myriad of biomarkers that help to characterize the tumor's distinct attributes. Behind this intricate network lies an array of genetic mutations, epigenetic modifications, unique pathophysiological conditions, and immune responses that not only dictate the tumor's behavior but also influence the surrounding brain environment.

This Special Issue aims to bridge the foundational knowledge of genetics, epigenetics, immunology and pathophysiology with the development of groundbreaking treatments. The primary focus is to shed light on the latest advancements in GBM that identify the genetic mutations, epigenetic alterations, immunological facets, biomarker discovery, and the tumor microenvironment's unique pathophysiology, which all represent both challenges and opportunities for drug delivery and targeted therapies.

We invite researchers and clinicians to present their original research manuscripts and review articles that present genomic, epigenomic, pathophysiological, immunological, and biomarker-centric data to develop a comprehensive understanding of GBM. We are particularly interested in research that elucidates the role of genetic and epigenetic factors, as well as immunological interactions and biomarkers, in GBM progression, the impact of the GBM microenvironment on therapeutic strategies, and the innovative methodologies employed to piece together this complex puzzle.

Dr. Felix Mircea Brehar
Prof. Dr. Alexandru Vladimir Ciurea
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• glioblastoma (GBM)
• therapeutic resistance
• immunological responses
• biomarkers
• genetic mutations
• epigenetic modifications
• pathophysiological conditions
• tumor microenvironment
• drug delivery
• targeted therapies